Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Aligos Therapeutics Inc.

    NASDAQ: ALGS · Real-Time Price · USD
    7.80
    -0.23 (-2.86%)
    At close: Jun 13, 2025, 3:59 PM
    7.89
    1.09%
    After-hours: Jun 13, 2025, 04:57 PM EDT

    Aligos Therapeutics Statistics

    Share Statistics

    Aligos Therapeutics has 6.11M shares outstanding. The number of shares has increased by -91.85% in one year.

    Shares Outstanding

    n/a
    		 6.11M

    Shares Change (YoY)

    n/a
    		 -91.85%

    Shares Change (QoQ)

    n/a
    		 76.5%

    Owned by Institutions (%)

    n/a
    		 25.82%

    Shares Floating

    n/a
    		 4.85M

    Failed to Deliver (FTD) Shares

    n/a
    		 2,766

    FTD / Avg. Volume

    n/a
    		 1.74%

    Short Selling Information

    The latest short interest is 552.79K, so 9.04% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 552.79K

    Short % of Shares Out

    n/a
    		 9.04%

    Short % of Float

    n/a
    		 10.63%

    Short Ratio (days to cover)

    n/a
    		 4.67

    Valuation Ratios

    The PE ratio is -1.9 and the forward PE ratio is -0.89. Aligos Therapeutics's PEG ratio is 0.

    PE Ratio

    n/a
    		 -1.9

    Forward PE

    n/a
    		 -0.89

    PS Ratio

    n/a
    		 63.27

    Forward PS

    n/a
    		 0.2

    PB Ratio

    n/a
    		 -8.61

    P/FCF Ratio

    n/a
    		 -3.09

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Aligos Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.86, with a Debt / Equity ratio of -0.29.

    Current Ratio

    n/a
    		 2.86

    Quick Ratio

    n/a
    		 2.86

    Debt / Equity

    n/a
    		 -0.29

    Debt / EBITDA

    n/a
    		 -0.09

    Debt / FCF

    n/a
    		 -0.1

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $56,357.14

    Profits Per Employee

    n/a
    		 $-1,874,442.86

    Employee Count

    n/a
    		 70

    Asset Turnover

    n/a
    		 0.06

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 331K

    Effective Tax Rate

    n/a
    		 -0.25%

    Stock Price Statistics

    The stock price has increased by -37.6% in the last 52 weeks. The beta is 2.69, so Aligos Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.69

    52-Week Price Change

    n/a
    		 -37.6%

    50-Day Moving Average

    n/a
    		 5.6

    200-Day Moving Average

    n/a
    		 15.67

    Relative Strength Index (RSI)

    n/a
    		 64.11

    Average Volume (20 Days)

    n/a
    		 159,288

    Income Statement

    In the last 12 months, Aligos Therapeutics had revenue of 3.94M and earned -131.21M in profits. Earnings per share was -20.94.

    Revenue

    n/a
    		 3.94M

    Gross Profit

    n/a
    		 1.32M

    Operating Income

    n/a
    		 -89.15M

    Net Income

    n/a
    		 -131.21M

    EBITDA

    n/a
    		 -89.15M

    EBIT

    n/a
    		 -89.15M

    Earnings Per Share (EPS)

    n/a
    		 -20.94
    Full Income Statement

    Balance Sheet

    The company has 37M in cash and 8.38M in debt, giving a net cash position of 28.62M.

    Cash & Cash Equivalents

    n/a
    		 37M

    Total Debt

    n/a
    		 8.38M

    Net Cash

    n/a
    		 28.62M

    Retained Earnings

    n/a
    		 -618.01M

    Total Assets

    n/a
    		 150.7M

    Working Capital

    n/a
    		 124.26M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -80.74M and capital expenditures -130K, giving a free cash flow of -80.87M.

    Operating Cash Flow

    n/a
    		 -80.74M

    Capital Expenditures

    n/a
    		 -130K

    Free Cash Flow

    n/a
    		 -80.87M

    FCF Per Share

    n/a
    		 -12.91
    Full Cash Flow Statement

    Margins

    Gross margin is 33.54%, with operating and profit margins of -2259.92% and -3326.01%.

    Gross Margin

    n/a
    		 33.54%

    Operating Margin

    n/a
    		 -2259.92%

    Pretax Margin

    n/a
    		 -3317.62%

    Profit Margin

    n/a
    		 -3326.01%

    EBITDA Margin

    n/a
    		 -2259.92%

    EBIT Margin

    n/a
    		 -2259.92%

    FCF Margin

    n/a
    		 -2050.01%

    Dividends & Yields

    ALGS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for ALGS is $70, which is 797.4% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $70

    Price Target Difference

    n/a
    		 797.4%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 1
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Aug 19, 2024. It was a backward split with a ratio of 1:25.

    Last Split Date

    n/a
    		 Aug 19, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:25

    Scores

    Altman Z-Score

    n/a
    		 -5.61

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist